Reports fourth quarter revenues of $1.0 billion, GAAP net loss of $(1.1) billion and GAAP EPS of $(2.91); loss includes approximately $0.2 ...

Reports fourth quarter revenues of $1.0 billion, GAAP net loss of $(1.1) billion and GAAP EPS of $(2.91); loss includes approximately $0.2 billion of non-cash charges related to manufacturing resizing ...

Moderna has been ordered to pay almost £44,000 after 12-year-olds were encouraged to join Covid vaccine trials with the ...

Moderna reported a bigger-than-expected quarterly loss on Friday, hit by a charge related to its efforts to scale down ...

Moderna swung to a loss in the last three months of the year after an early launch of its updated Covid-19 vaccine shifted sales out of the fourth quarter.

The vaccine maker Moderna had no Valentine’s Day chocolates for investors when its fourth-quarter financial results came out ...

Covid vaccine maker Moderna posted a mixed fourth-quarter report Friday as sales topped Wall Street's projections, but on ...

Moderna has filed complaints in the US and Germany claiming that the mRNA technology used to make Pfizer and BioNTech's Comirnaty vaccine infringes multiple patents that cover its own Spikevax shot.

4/BA.5 – for people aged 12 and over. Moderna's updated Spikevax shot includes 25 µg of spike protein mRNA from BA.4/BA.5 and 25 µg from the original strain of SARS-CoV-2, and has been ...

In this article, we are going to take a look at where Moderna, Inc. (NASDAQ:MRNA) stands against the other healthcare stocks. McKinsey reported that, since 2019, the US healthcare industry ...

Moderna (MRNA) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended December 2024. This widely-known consensus outlook gives ...

Janney Montgomery Scott LLC lowered its holdings in Moderna, Inc. (NASDAQ ... and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein ...